Polyoxazoline based thermal latent curing agents for thermoset resins
US-2024270940-A1 · Aug 15, 2024 · US
US12018125B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12018125-B2 |
| Application number | US-201816623513-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2018 |
| Priority date | Jun 20, 2017 |
| Publication date | Jun 25, 2024 |
| Grant date | Jun 25, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided is an (A)-(B)-(A) triblock copolymer comprising two hydrophilic polymer blocks (A) as further defined herein, and a polymer block (B), said polymer block (B) comprising at least one type of repeating unit of the following formula (I) wherein R 1 is an aliphatic hydrocarbon group which is optionally substituted with one or more of —OR 5 , —SR 5 , —NR 6 R 7 , —(NR 6 R 7 R 8 )+, —CONR 6 R 7 , —C(O)OR 9 and —C(O)R 10 , wherein R 5 to R 10 are independently selected from H, aliphatic and aromatic residues, and wherein R 1 is selected such that the polymer block (B) is more hydrophobic than the polymer block (A); and compositions, such as pharmaceutical compositions, formed with the block copolymer.
Opening claim text (preview).
The invention claimed is: 1. An (A)-(B)-(A) triblock copolymer comprising two hydrophilic polymer blocks (A), wherein a structure of the polymer blocks (A) is indicated independently for each of the two polymer blocks, by the following formula (IIa) wherein R 2 is methyl or ethyl; and m is from 20 to 50; and a polymer block (B), wherein a structure of the polymer block (B) is indicated by the following formula (Ia) wherein R 1 is a C3-C9 alkyl group and n is from 10 to 50; wherein the ratio of repeating units contained in polymer blocks (A) to repeating units contained in polymer block (B), in terms of the numbers of repeating units, ranges from 7:1 to 2:1. 2. The (A)-(B)-(A) triblock copolymer of claim 1 , wherein R 2 is methyl. 3. The (A)-(B)-(A) triblock copolymer of claim 1 , wherein R 1 is a C3-C5 alkyl group. 4. The (A)-(B)-(A) triblock copolymer of claim 1 , wherein R 1 is selected from propyl and butyl. 5. The (A)-(B)-(A) triblock copolymer of claim 1 , wherein n is 15 or more. 6. The (A)-(B)-(A) triblock copolymer of claim 1 , wherein the ratio of repeating units contained in polymer blocks (A) to repeating units contained in polymer block (B), in terms of the numbers of repeating units, ranges from 7:1 to 3:1. 7. A composition comprising one or more triblock copolymers as defined in claim 1 in combination with one or more compounds to be solubilized. 8. The composition of claim 7 , wherein a weight ratio of the weight of the compound(s) to be solubilized to the weight of the triblock copolymer(s) is at least 0.1:1.0. 9. The composition of claim 7 , which is a solid composition. 10. The composition of claim 7 , which is a solution, an emulsion or a suspension. 11. The composition of claim 10 , wherein the composition comprises micelles which are formed by the triblock copolymer(s) and which incorporate the compound(s) to be solubilized. 12. The composition of claim 7 , wherein the one or more triblock copolymers form micelles which incorporate the compound(s) to be solubilized. 13. The composition of claim 7 , wherein the one or more compounds to be solubilized are selected from therapeutically active agents, agents for use in diagnosis, fungicides, pesticides, insecticides, herbicides, phytohormones and catalytically active compounds. 14. The composition of claim 7 , which is a pharmaceutical composition which comprises one or more therapeutically active agents as the compound(s) to be solubilized. 15. The composition of claim 14 , wherein the therapeutically active agent comprises a chemotherapeutic agent which is suitable for the treatment of cancer. 16. A method for treatment of cancer, comprising administrating a therapeutically effective amount of the composition of claim 15 to a patient in need thereof. 17. A method for the preparation of a pharmaceutical composition, said method comprising a step of combining a triblock copolymer of claim 1 with one or more therapeutically active agent as compounds to be solubilized. 18. A method for solubilizing one or more compounds in an aqueous environment, comprising a step of incorporating the compound(s) as compounds to be solubilized into a composition of claim 7 . 19. A method for detection of one or more compounds which interact with a target of interest in a screening test, said method comprising steps of providing one or more compounds to be subjected to a detection method, separately incorporating the compound(s) as compounds to be solubilized each into a composition as defined in claim 7 , and subjecting the compositions to the screening test.
Polyamines · CPC title
Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42}) · CPC title
Polyamines · CPC title
on to nitrogen-containing macromolecules · CPC title
having four-membered rings, e.g. taxol · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.